Symptoms that mimic fibroids make diagnosing uterine sarcoma a rare and confounding cancer. In 2014, Dionne Shepperson, then 40 and pregnant, began feeling weak and faint. Because she had in the past ...

Malignant fibrous histiocytoma (MFH) is a type of cancer that typically occurs in soft tissues, such as the muscles and tendons. When it starts in the bones, doctors call it MFH of the bone. The up-to ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Kimberley Nix was a 28-year-old medical resident when she was diagnosed with metastatic sarcoma. Today, she continues her studies while sharing her journey on social media Stephanie Sengwe is a pop ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 56-year-old man presented to the ED with 3 months of ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial. This is an ASCO Meeting Abstract from ...

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...